Leptin Protein (26-006897)

The National Institute of Health (NIH) intends to negotiate and award a purchase order without providing for full and open competition to BIO-TECHNE SALES CORP. The purpose of this requirement is to provide a firm-fixed-price contract for Recombinant Rat Leptin Protein in the Critical Care Medicine Department within the NIH Clinical Center. The Critical Care Medicine Department conducts active research programs in bedside clinical investigation, research in animal models, and molecular biology.

Full-time research activities commence at the beginning of the second year of the fellowship for fellows interested in the critical care subspecialty alone. For those interested in dual board eligibility, their second-year program is individually designed and consists of clinical rotations required for board eligibility in the particular subspecialties. After completion of second subspecialty training, full-time research activities commence. Major topics of research interest within the Department include:

The immunopathogenesis of septic shock Studies of immune cellular function in respiratory distress syndrome, asthma, and other forms of severe pulmonary disease Biomarkers and novel therapies in pulmonary arterial hypertension Biomarkers of acute cellular rejection in heart transplantation Diagnosis and treatment of opportunistic infections Studies of immune cellular function and therapy of AIDS Pathogenesis and treatment of anthrax Emerging infectious diseases Biology and clinical effects of nitric oxide acute lung injury pulmonary arterial hypertension role as transcription regulatory factor Functional genomics of critical illness human acute inflammation animal model of septic shock and multiple organ failure pulmonary arterial hypertension solid organ transplantation Emerging Infectious Disease This product is a sole source item as it’s manufactured by the supplier.

This material will be use on in vivo experiment under ORWH Innovation Awards SEX- AND OBESITY-ASSOCIATED MECHANISMS AND THERAPEUTIC TARGETS IN PULMONARY ARTERIAL HYPERTENSION. Biological material for animal treatments can’t be changed as we will incur in additional testing, additional testing subjects and validation and in vivo results can’t be compared. Finally, a review of the GSA Advantage, Dynamic Small Business Search, and previous government acquisitions returned no results that meet all of the requirements. Therefore, only BIO-TECHNE SALES CORP. is capable of meeting the needs of this requirement.